Wall Street analyst estimates for Vyome Holdings, Inc. (HIND): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 0.33 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-13 | $-0.16 | ||
| 2026-08-12 | $-0.10 | $-0.19 | +47.4% |
| 2026-05-19 | $-0.15 | $-0.15 | +0.0% |
| 2026-03-26 | $-0.47 | $-0.47 | +0.0% |
| 2025-11-14 | $-3.12 | $-0.11 | -2736.4% |
| 2025-08-14 | $-2.25 | ||
| 2025-05-21 | $18.98 | ||
| 2025-04-04 | $-47.25 | $-406.00 | +88.4% |
Valuation Ratios
| Price / Book | 2.32 |
| EV / EBITDA | -0.67 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $786660 | $1.3M | $606710 | $15.1M | $11.3M | $13.6M | $11.2M | $8.7M | $8.0M | $319714 |
| Cost of Revenue | $431476 | $936386 | $164299 | $5.8M | $5.0M | $5.3M | $4.4M | $3.1M | $2.9M | $112928 |
| Gross Profit | $355184 | $350768 | $442411 | $9.3M | $6.3M | $8.3M | $6.8M | $5.5M | $5.1M | $206786 |
| Research & Development | $5.2M | $5.8M | $5.7M | $3.1M | $3.5M | $2.4M | $2.5M | $2.3M | $1.8M | $588258 |
| Selling, General & Admin | $18.0M | $26.0M | $19.3M | $22.1M | $15.2M | $33.2M | $31.3M | $17.9M | $9.9M | $2.4M |
| Operating Expenses | $23.2M | $31.8M | $25.0M | $33.8M | $18.7M | $66.2M | $33.9M | $20.2M | $12.8M | $3.0M |
| Operating Income | -$22.8M | -$31.4M | -$38.5M | -$24.5M | -$12.5M | -$57.9M | -$27.1M | -$14.6M | -$7.7M | -$2.7M |
| EBITDA | -$19.5M | -$34.4M | -$37.0M | -$72.9M | -$18.1M | -$60.6M | -$44.3M | -$11.2M | -$6.6M | -$10.3M |
| Interest Expense | $4.1M | $3874 | $12000 | $451000 | $2.0M | $832000 | $113000 | 0 | 0 | $146641 |
| Pre-tax Income | -$23.4M | -$36.1M | -$38.7M | -$75.1M | -$21.8M | -$63.4M | -$46.6M | -$11.3M | -$7.1M | -$10.5M |
| Income Tax | 0 | -$2.3M | -$3.4M | -$893000 | -$181000 | -$274000 | -$380000 | $52000 | $39000 | 0 |
| Net Income | -$23.4M | -$33.8M | -$81.2M | -$74.2M | -$21.6M | -$63.1M | -$46.2M | -$11.4M | -$7.1M | -$10.3M |
| EPS | $-10548750.00 | $-4524000.00 | $-4270786.00 | $-1094068.00 | $-503023.26 | $-419004.00 | $-157897.00 | $-2771.94 | $-345.74 | $-4.75 |
| EPS (Diluted) | $-10548750.00 | $-4524000.00 | $-4270786.00 | $-1094068.00 | $-503023.26 | $-419004.00 | $-157897.00 | $-2771.94 | $-345.74 | $-4.75 |
| Shares Outstanding (Diluted) | 0 | $8 | $9 | $22 | $43 | $151 | $293 | $4107 | $20622 | $2.2M |
Price
| Price | $1.96 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ARMP · CCCC · CDXS · CGEN · IMDX · IPHA · NVCT
Explore sector: Healthcare · Biotechnology
More sections of HIND: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks